Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2010
Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.
Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Guideline
- The nomograms for predicting overall and cancer-specific survival in elderly patients with early-stage lung cancer: A population-based study using SEER database.Frontiers in public health · 2022Trial
- Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings.JTO clinical and research reports · 2026Article
- Role of genetic alterations on outcomes for pulmonary resection in oligometastatic non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Development and validation of nomograms to predict early death for elderly lung cancer patients.Frontiers in surgery · 2023Article
- Article
- Timing, Sites, and Correlates of Lung Cancer Recurrence.Clinical lung cancer · 2020Article
- QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.Clinical lung cancer · 2020Article
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Observational
- Cell-penetrating peptide conjugates to enhance the antitumor effect of paclitaxel on drug-resistant lung cancer.Drug delivery · 2017Article
- Retrospective analysis of lung cancer patients treated with supportive care alone.International journal of clinical oncology · 2017Article
- Stigmatic and Sympathetic Attitudes Toward Cancer Patients Who Smoke: A Qualitative Analysis of an Online Discussion Board Forum.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Article
- Clinician Perspectives on Current Issues in Lung Cancer Drug Development.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016Review
- Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.Journal of neuro-oncology · 2016Article
- Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study.BMJ open · 2015Article
- Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified.Current oncology (Toronto, Ont.) · 2015Article
- Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.Journal of the National Cancer Institute · 2015Article
- Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis.American journal of cancer research · 2015Article
- Impact of prior cancer on eligibility for lung cancer clinical trials.Journal of the National Cancer Institute · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionChemotherapy prolongs survival without substantially impairing quality of life for medically fit patients with advanced non-small cell lung cancer (NSCLC), but population-based studies have shown that only 20 to 30% of these patients receive chemotherapy. These earlier studies have relied on Medicare-linked Surveillance, Epidemiology, and End Results (SEER) data, thus excluding the 30 to 35% of lung cancer patients younger than 65 years. Therefore, we determined the use of chemotherapy in a contemporary, diverse NSCLC population encompassing all patient ages.
methodsWe performed a retrospective analysis of patients diagnosed with stage IV NSCLC from 2000 to 2007 at the University of Texas Southwestern Medical Center. Demographic, treatment, and outcome data were obtained from hospital tumor registries. The association between these variables was assessed using univariate analysis and multivariate logistic regression.
resultsIn all, 718 patients met criteria for analysis. Mean age was 60 years, 58% were men, and 45% were white. Three hundred fifty-three patients (49%) received chemotherapy. In univariate analysis, receipt of chemotherapy was associated with age (53% of patients younger than 65 years versus 41% of patients aged 65 years and older; p = 0.003) and insurance type (p < 0.001). In a multivariate model, age and insurance type remained associated with receipt of chemotherapy. For individuals receiving chemotherapy, median survival was 9.2 months, compared with 2.3 months for untreated patients (p < 0.001).
conclusionsIn a contemporary population representing the full age range of patients with advanced NSCLC, chemotherapy was administered to approximately half of all patients-more than twice the rate reported in some earlier studies. Patient age and insurance type are associated with receipt of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.